The Tiny Isotope That Could Change Cancer Treatment and Create the Next Generation of 10-Bagger Stocks

Every now and then, a technology emerges that has the potential to reshape an entire industry.

Artificial intelligence needed semiconductors. The internet needed fiber optic networks. The shale revolution needed horizontal drilling.

Targeted alpha therapy may need Actinium-225.

Most investors have never heard of it. Most oncologists are still learning how to use it. Yet Ac-225 is increasingly becoming one of the most important building blocks in the future of cancer treatment.

The reason is simple. Early clinical data suggest that Actinium-225 may be capable of delivering extraordinarily powerful radiation directly to cancer cells while minimizing damage to surrounding healthy tissue.

If those early results continue to hold up, Ac-225 could become one of the most valuable raw materials in medicine.

The opportunity is not limited to drug developers. Investors may find opportunities in isotope producers, manufacturing companies, and radiopharmaceutical developers building the infrastructure needed to support an entirely new generation of cancer treatments.

If the name "Ac-225" sounds familiar, it's because your inbox has probably been flooded with newsletter pitches promising millions from this technology — provided you hand over $2,000 first.

I didn't like that. So I did the digging myself — went through every publicly traded company with meaningful Ac-225 exposure, separated the serious ones from the noise, and identified the names that actually deserve attention based on their pipeline, their position in the value chain, and their ability to survive long enough to matter. The full list is below, and it didn't cost you $2,000.

But a list of promising stocks is still just a list. The harder ongoing question is which ones are actually worth acting on — the ones where insiders are buying, where institutions are taking positions, where the clinical catalysts are real and the balance sheet won't dilute you into oblivion before the thesis plays out.

That's what the new Flagship Report Premium biotech watchlist is for. Not recommendations. Not a portfolio. A curated hitlist of the most promising names — tracked for insider and institutional buying, upcoming catalysts, data releases, and financial soundness. The people who know these companies best are voting with their own money. The watchlist tells you where they're putting it.

A new edition goes out every month, exclusively to Premium members. Upgrade here to get it.

Now, back to Actinium-225.

Actinium-225 is a radioactive isotope used in targeted alpha therapy.

Scientists attach the isotope to molecules that seek out specific cancer cells. Once the drug reaches its target, Ac-225 emits alpha particles that destroy cancer cells with tremendous force over an extremely short distance.

Think of traditional chemotherapy as carpet bombing.

Think of Actinium-225 as a precision-guided missile.

Ac-225 is particularly attractive because its decay chain produces four alpha particle emissions. Those alpha particles deliver massive amounts of energy directly into tumor cells while limiting exposure to nearby healthy tissue.

Researchers believe Ac-225 may ultimately prove effective against cancers that survive chemotherapy, immunotherapy, hormone therapy, and even first-generation radiopharmaceuticals.

The most advanced work today is occurring in prostate cancer, but researchers are also exploring applications in leukemia, breast cancer, neuroendocrine tumors, pancreatic cancer, ovarian cancer, lung cancer and numerous other solid tumors.

For decades, cancer treatment evolved from surgery to chemotherapy to targeted therapies to immunotherapy. Targeted alpha therapy may represent the next major step in that evolution.

If that happens, we are not discussing another incremental advance.

We are discussing a new therapeutic platform.

The strongest signal so far came from Novartis.

At ASCO 2026, the company reported encouraging early-stage data from an Ac-225 prostate cancer program. More than half of patients previously treated with Pluvicto achieved PSA reductions exceeding 50%. Response rates exceeded 85% in treatment-naive patients.

Those results are early and toxicity remains a challenge. Dry mouth, salivary gland damage and anemia remain areas of active research.

Nevertheless, pharmaceutical companies do not spend billions of dollars chasing technologies they believe have little chance of success.

Over the last three years, the industry's largest players have aggressively expanded their radiopharmaceutical capabilities.

AstraZeneca acquired Fusion Pharmaceuticals.

Bristol Myers Squibb acquired RayzeBio.

Eli Lilly acquired Point Biopharma and invested in isotope production.

Novartis continues to expand manufacturing capacity.

Bayer has assembled one of the largest Actinium supply networks in the world.

That level of investment suggests management teams see targeted alpha therapy becoming one of the most important oncology categories of the next decade.

Nobody knows exactly how large the Ac-225 market becomes.

What we do know is that the overall radiopharmaceutical market is expected to expand dramatically over the next decade. Industry forecasts suggest radiopharmaceutical revenues could exceed $20 billion annually while targeted alpha therapy alone could become a multibillion-dollar category.

The most optimistic scenario is straightforward.

Today Ac-225 is primarily being studied in advanced prostate cancer.

Tomorrow it may be used in breast cancer, leukemia, lung cancer, neuroendocrine tumors, ovarian cancer, pancreatic cancer and many other cancers.

Every successful indication increases demand for isotope production.

That is why supply has become one of the most important themes in the entire sector.

Prostate cancer remains the industry's primary focus.

Among the most important programs currently underway are Novartis' AAA817 and Ac-225 PSMA-617 programs, Bayer's Ac-225 PSMA-Trillium program, multiple AcTION studies, UCLA investigator-sponsored Ac-225 programs and various next-generation PSMA-targeted alpha therapies.

Researchers are also evaluating Ac-225 in leukemia, breast cancer and other difficult-to-treat tumors.

Hundreds of radiotheranostic studies are now underway globally. If even a fraction of these programs prove successful, demand for Actinium-225 could increase dramatically.

Most investors are focused on the drugs.

The more interesting opportunity may be the isotope itself.

Actinium-225 is difficult to produce.

Global supply remains limited.

Every major pharmaceutical company developing Ac-225 therapies is competing for access to a relatively small amount of isotope production.

Whenever an industry enters a rapid growth phase, the companies selling the picks and shovels often generate extraordinary returns.

That may prove true here as well.

The biggest winners from the internet boom were not necessarily internet companies. The biggest winners from artificial intelligence have often been the companies supplying the infrastructure.

The same pattern could emerge in radiopharmaceuticals.

Every successful Ac-225 therapy requires Actinium-225.

There is no substitute.

There is no workaround.

There is no software update that creates additional isotope supply.

If targeted alpha therapy succeeds, somebody has to produce the isotope.

That simple reality could create enormous opportunities for investors.

Among all publicly traded companies, ATNM may offer the most direct exposure to the Ac-225 theme.

The company's entire business is built around Actinium-based therapies. Unlike many radiopharmaceutical companies that simply purchase isotopes from suppliers, Actinium possesses significant expertise in isotope production, radiochemistry, intellectual property and targeted alpha therapy development.

Most investors still associate the company with Actimab-A.

The more interesting story may be ATNM-400.

Management is positioning ATNM-400 as a next-generation Ac-225 radioconjugate with applications across multiple solid tumors. Early data suggest activity in prostate, breast and lung cancer models.

That is potentially important.

Most radiopharmaceutical companies are pursuing single-disease opportunities.

ATNM is attempting to build a platform.

The company remains highly speculative. Clinical failure remains possible and additional capital raises are almost inevitable.

However, the company also possesses one of the smallest valuations among meaningful Ac-225 developers. If targeted alpha therapy becomes a major treatment category and ATNM successfully advances its pipeline, investors may not be looking at a single-product success story.

They may be looking at a platform company.

The comparison investors should remember is that Fusion Pharmaceuticals sold for roughly $2 billion. RayzeBio sold for roughly $4 billion. Point Biopharma sold for roughly $1.4 billion.

ATNM remains valued at a fraction of those figures.

If management executes and Ac-225 therapies become a significant part of oncology treatment, a 10-bagger may not be an aggressive outcome. The possibility exists for returns substantially beyond that level.

This is probably the highest-risk and highest-reward Actinium investment available in public markets today.

Telix may be the highest-quality company discussed in this article.

Most investors know Telix because of Illuccix, one of the leading prostate cancer imaging products.

That view may eventually prove far too narrow.

What Telix is quietly building resembles a fully integrated radiopharmaceutical platform spanning diagnostics, therapeutics, isotope production, manufacturing and distribution.

The company already generates revenue.

It already has customers.

It already has manufacturing expertise.

It already has regulatory experience.

Most competitors are still trying to build those capabilities.

Management is using its existing commercial platform to build a much larger theranostics franchise. Its TLX592 program incorporates Ac-225 targeted alpha therapy for prostate cancer and could become an important future growth driver.

Investors often underestimate the power of a company that successfully transitions from a single-product story into a platform story.

The global radiopharmaceutical market remains in its infancy.

If targeted alpha therapy becomes a standard treatment for prostate cancer and eventually expands into additional tumor types, Telix could emerge as one of the dominant global radiopharmaceutical franchises.

Many investors look at today's valuation and assume the largest gains have already occurred.

That assumption may prove incorrect.

A decade from now investors may view Telix the way they now view the early leaders in biologics and immunotherapy.

The path to a 10-bagger is more challenging because Telix already carries a multibillion-dollar valuation.

It is not impossible.

CATX is not technically an Ac-225 company.

Its platform centers on Lead-212 alpha therapies.

That distinction matters less than many investors realize.

The company is still participating directly in the targeted alpha therapy revolution.

Its lead programs target neuroendocrine tumors, melanoma and other solid tumors. Management is simultaneously building manufacturing infrastructure and isotope capabilities that could become increasingly valuable as alpha therapy adoption expands.

The bull case is straightforward.

Lead-212 may ultimately prove easier to manufacture and distribute than Actinium-225.

If that happens, CATX could emerge as one of the industry's major independent alpha therapy companies.

The company remains highly speculative and clinical-stage. However, the valuation remains small enough that successful clinical results could create enormous returns for investors willing to accept substantial risk.

This may be the most overlooked stock in the entire article.

Investors are obsessed with drug developers.

Meanwhile, almost nobody is paying attention to isotope production.

That could be a mistake of enormous proportions.

Through its ownership interest in PanTera, IBA has exposure to one of Europe's most ambitious Actinium-225 production initiatives.

Most investors have never heard of PanTera.

That may eventually change.

Imagine a scenario where Novartis, Bayer, AstraZeneca, Bristol Myers, Eli Lilly and dozens of smaller biotechnology companies all move successful Ac-225 therapies into commercial production.

Demand could increase by orders of magnitude.

Supply remains constrained today.

That supply shortage could become one of the defining investment themes of the next decade within radiopharmaceuticals.

When investors think about the future, they tend to focus on the companies developing the drugs.

What if the real bottleneck turns out to be isotope production?

What if the most valuable assets become the facilities capable of reliably producing commercial quantities of Ac-225?

That is the bet investors are making when they buy IBA.

The company is not dependent on a single clinical trial.

It is not dependent on a single FDA decision.

It is not dependent on one therapy succeeding.

It benefits from industry-wide growth.

Those are often the situations that create surprisingly large long-term returns.

If Ac-225 becomes as important as many industry participants believe, IBA could eventually be viewed as one of the most strategically valuable suppliers in the entire ecosystem.

Among the supply-side names, IOBCF may possess the greatest potential to surprise investors over the next decade.

BWXT may be the most important infrastructure company in the Ac-225 ecosystem.

Every successful Ac-225 treatment requires isotope supply.

BWXT is one of the few publicly traded companies capable of producing Actinium-225 at commercial scale.

The company does not need to guess which drug ultimately wins.

It simply needs more drugs to succeed.

As demand grows, isotope suppliers may gain pricing power and strategic importance. Pharmaceutical companies are already signing long-term supply agreements because they understand the value of reliable isotope access.

BWXT is unlikely to become a 10-bagger from current levels.

However, it may become one of the most important infrastructure beneficiaries of the entire Ac-225 trend.

Bayer may be the most underappreciated Ac-225 story among large pharmaceutical companies.

Most investors continue focusing on litigation, crop science concerns and operational challenges.

Meanwhile, Bayer has quietly assembled one of the most comprehensive Actinium-225 supply networks in the world.

The company has secured relationships with multiple isotope producers and continues advancing Ac-225 therapies through clinical development.

If targeted alpha therapy becomes one of the most important oncology breakthroughs of the decade, Bayer could emerge as one of the major beneficiaries.

The irony is that investors may currently be getting much of that opportunity for free.

Novartis is currently the industry leader in radioligand therapy.

The company already owns Pluvicto and Lutathera, giving it manufacturing expertise, regulatory relationships and physician networks that few competitors can match.

Its Ac-225 programs are viewed by many industry observers as the next generation of targeted radiotherapy.

Novartis may not deliver venture-capital-style returns, but it remains one of the most important companies shaping the future of the sector.

The most exciting aspect of Actinium-225 is not the isotope itself.

It is what the isotope represents.

For decades, cancer treatment evolved from surgery to chemotherapy to targeted therapies to immunotherapy.

Targeted alpha therapy could become the next major step in that evolution.

If that happens, we are not discussing incremental improvements.

We are discussing the creation of a new therapeutic platform capable of treating multiple cancers across potentially millions of patients.

When entirely new industries emerge, extraordinary investment returns often follow.

Most of the companies discussed here will not become 10-baggers.

History never works that way.

One or two of them might.

Among the names discussed, ATNM, TLX and IOBCF stand out as particularly interesting because they each offer exposure to different parts of the value chain.

ATNM offers leverage to breakthrough drug development.

TLX offers exposure to the emergence of a global radiopharmaceutical platform.

IOBCF offers exposure to what could become one of the industry's most critical bottlenecks: isotope production.

The winners may not ultimately be the companies treating cancer.

The winners may be the companies supplying the isotope that makes those treatments possible.

That is why the Actinium-225 story deserves attention today, while most investors have never even heard of it.

I've given you the full universe here, and every name on this list deserves attention. But a list is not a thesis, and a thesis is not a position. The next step — tracking which of these have insider buying, institutional accumulation, clean balance sheets, and real catalysts on the horizon — is exactly what the Flagship Report Premium biotech watchlist is for, launching this month.

Among the names in this article, several will be on it. The ones that aren't didn't make the cut.

If you want to know which is which, upgrade to Premium now and you'll get the watchlist the moment it drops.